Human F-ATP synthase as a drug target

Pharmacol Res. 2024 Nov:209:107423. doi: 10.1016/j.phrs.2024.107423. Epub 2024 Sep 19.

Abstract

Practical and conceptual barriers have kept human F-ATP synthase out of reach as a target for the treatment of human diseases. Although this situation has persisted for decades, it may change in the near future. In this review the principal functionalities of human F-ATP synthase--proton motive force / ATP interconversion, membrane bending and mitochondrial permeability transition--are surveyed in the context of their respective potential for pharmaceutical intervention. Further, the technical requirements necessary to allow drug designs that are effective at the multiple levels of functionality and modality of human F-ATP synthase are discussed. The structure-based development of gastric proton pump inhibitors is used to exemplify what might be feasible for human F-ATP synthase. And finally, four structural regions of the human F-ATP synthase are examined as potential sites for the development of structure based drug development.

Keywords: ATP synthase; FoF1 ATPase; OXPHOS; drug design; membrane protein; mitochondria.

Publication types

  • Review

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Humans
  • Mitochondrial Proton-Translocating ATPases / antagonists & inhibitors
  • Mitochondrial Proton-Translocating ATPases / chemistry
  • Mitochondrial Proton-Translocating ATPases / metabolism
  • Proton Pump Inhibitors* / chemistry
  • Proton Pump Inhibitors* / pharmacology
  • Proton Pump Inhibitors* / therapeutic use
  • Proton-Translocating ATPases / antagonists & inhibitors
  • Proton-Translocating ATPases / chemistry
  • Proton-Translocating ATPases / metabolism

Substances

  • Proton Pump Inhibitors
  • Mitochondrial Proton-Translocating ATPases
  • Proton-Translocating ATPases
  • Adenosine Triphosphate